Collaboration announced between Sonrai and AOA Dx for speeding up the creation of a diagnostic test for ovarian cancer
In a significant move for the field of cancer diagnostics, Sonrai Analytics and AOA Dx have announced a strategic partnership aimed at advancing AOA's multi-omic liquid biopsy test for ovarian cancer. This collaboration, announced in May 2025, seeks to leverage AI-driven tools to improve the test's capabilities for early detection and personalized treatment of ovarian cancer.
The partnership focuses on enhancing the non-invasive liquid biopsy technology that analyzes multiple molecular biomarkers, such as circulating tumor DNA and cells. This approach supports deep genetic and molecular profiling of tumors in bodily fluids, facilitating more precise and less invasive cancer diagnostics compared to traditional tissue biopsies.
AOA will leverage Sonrai's cloud-based advanced analytics platform, pharma-grade data infrastructure, and bioinformatic expertise to integrate and analyze multi-modal data. The Sonrai Discovery platform will enable AOA to store and manage their clinical data in role-based environments, allowing controlled access, workspace isolation, cross-functional collaboration, and real-time performance tracking.
Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines within a secure, cloud-native environment. Prof. Darragh McArt, CEO and Founder of Sonrai Analytics, stated that the partnership will unlock deeper insights from complex multi-modal data and accelerate the validation of biomarkers.
Meanwhile, PathAI has received FDA clearance for its AISight Dx platform, a development reported in "Digital Health & AI News". The article does not provide details about the nature or purpose of the FDA clearance.
Elsewhere, AbbVie has received marketing authorisation from MHRA, but the nature or purpose of the marketing authorisation is not specified in the available reports.
In other news, Dxcover has strengthened its leadership with new scientific advisors and board members, described as "world-class", according to reports in "News". However, the specific details about these new appointments were not provided.
The test developed by AOA Dx diagnoses ovarian cancer in women experiencing vague abdominal symptoms. It leverages a combination of novel gangliosides, lipids, and proteins to provide a comprehensive analysis. The partnership aims to advance the development of the diagnostic test through a multi-omic biomarker validation strategy.
Dr Abigail McElhinny, Chief Scientific Officer of AOA Dx, stated that the partnership will allow AOA to integrate and manage their in-house development data, cross-reference it with public datasets, and analyze it seamlessly within one centralized environment. This collaboration is expected to contribute significantly to the early detection and personalized treatment of ovarian cancer.
- The partnership between Sonrai Analytics and AOA Dx, as announced in May 2025, involves the advancement of AOA's multi-omic liquid biopsy test for ovarian cancer using AI-driven tools, focusing on enhancing non-invasive technology that analyzes multiple molecular biomarkers, such as circulating tumor DNA and cells.
- Sonrai's cloud-based advanced analytics platform, pharma-grade data infrastructure, and bioinformatic expertise will be utilized by AOA to integrate and analyze multi-modal data, enabling them to store and manage their clinical data in role-based environments for controlled access, workspace isolation, cross-functional collaboration, and real-time performance tracking.
- The collaboration between the two companies is expected to contribute significantly to the early detection and personalized treatment of ovarian cancer by unlocking deeper insights from complex multi-modal data and accelerating the validation of biomarkers.
- Meanwhile, separate news reports mention the receipt of FDA clearance for PathAI's AISight Dx platform, coupled with AbbVie receiving marketing authorization from MHRA, and Dxcover strengthening its leadership with the addition of world-class scientific advisors and board members, though the specific details of these developments are not yet known.
